Research shows anti-HIV medicines can cause damage to fetal hearts

November 21, 2014

A study by a Wayne State University and Children’s Hospital of Michigan, Detroit Medical Center research team is shedding new light on the troubling question of whether the drugs often given to HIV-positive pregnant women can cause significant long-term heart problems for the non-HIV-infected babies they carry.

The study recently published in the journal AIDS shows that while the HIV medications have been successful in helping to prevent the transmission of the virus from mother to infant, they are associated with persistently impaired development of heart muscle and reduced heart performance in non-HIV-infected children whose mothers received the medicines years earlier.

“What our study indicates is that there’s potentially a long-term price to be paid for protecting the children of HIV-infected mothers from the virus,” said Steven E. Lipshultz, M.D., pediatrician-in-chief at the Children’s Hospital of Michigan and chair of pediatrics for the Wayne State University School of Medicine. Dr. Lipshultz is a specialist in the study of long-term toxic cardiac effects among children affected by cancer and HIV drug therapies.

“These medicines have been very effective at reducing the rate of transmission of HIV from mother to child,” added Dr. Lipshultz, the lead author of the study, “but the findings we’ve just published show clearly that further investigation of their long-term impact on the heart health of the children involved is needed.

“Thanks to the new anti-HIV medications, the rate of transmission has been lowered from 26 percent to less than 1 percent during the past few decades, and that has been a miracle of life for the children involved. Still, we don’t want to be protecting these children from one disease, only to give them another one.”

The study compared heart development and long-term heart functioning in 428 uninfected children of HIV-infected mothers to children who had not been exposed to HIV from 2007 to 2012. The results pointed to a significant association between lagging heart muscle development and impaired pumping ability in the children of the HIV-infected mothers who had received the medications.

“These findings clearly indicate the need for further study,” said Dr. Lipshultz, while pointing to one of the study’s key conclusions: “Subclinical differences in left ventricular structure and function with specific in-utero antiviral exposures indicate the need for a longitudinal study to assess long-term cardiac risk and cardiac monitoring recommendations.”

Dr. Lipshultz, a nationally recognized expert on pediatric cardiac care who 20 years ago led the effort to found the nation’s only registry of pediatric cardiomyopathy, said the study is a “compelling example of how clinical research can be effective in helping to shed light on complex problems in pediatric health care.”

The Children’s Research Center of Michigan team, located at the Children’s Hospital of Michigan, involved with this National Institutes of Health-supported multicenter study includes James Wilkinson, M.D., associate director of the center and professor of pediatrics, and research assistant Joslyn Westphal, M.P.H.

Dr. Wilkinson stressed the study “raises the question of how much do we know about the long-term safety of drugs given to children?” He is concerned that “pediatric drug studies remain particularly limited. The lack of information about the long-term safety of drugs prescribed for children is a special worry, both for drugs that may be used for decades for chronic conditions and for drugs for which short-term use may be found to harm children’s growth and development months or years later. Although these are effective medicines for children, in order to understand their safety, long-term pediatric safety studies are needed to potentially allow future options for improvement if serious safety risks are identified.”

“At the end of the day, our goal at the Children’s Hospital of Michigan is to provide the very best possible care for our patients,” Dr. Lipshultz said. “Studies like this one are crucially important for meeting that challenge.”

The PHACS (Pediatric HIV/AIDS Cohort Study) is the largest US government study of pediatric HIV and AIDS with over 30 centers. It is a trans-National Institutes of Health study with 10 NIH institutes and centers participating and funding PHACS. Since PHACS's inception more than a decade ago, Dr. Lipshultz has been the NIH-funded cardiology leader of PHACS, a member of its scientific leadership group, and the inaugural and only chair of the NIH PHACS Cardiovascular Task Force, the group which led this study.

For more than 125 years, the Children’s Hospital of Michigan is the first hospital in the state dedicated exclusively to the treatment of children. With more than 40 pediatric medical and surgical specialties and services, the hospital is a leader internationally in neurology and neurosurgery, cardiology, oncology, and diagnostic services; it is ranked one of America’s best hospitals for children by US News and World Report and Parent Magazine and is recognized for quality and safety by the Leapfrog Group. The Children’s Hospital of Michigan is one of eight hospitals operated by the Detroit Medical Center (DMC).

Wayne State University is a premier urban research institution offering more than 400 academic programs through 13 schools and colleges to nearly 32,000 students. Its School of Medicine is the largest single-campus medical school in the nation with more than 1,200 medical students. In addition to undergraduate medical education, the school offers master’s degree, Ph.D. and M.D.-Ph.D. programs in 14 areas of basic science to about 400 students annually.